L
L. Doug Case
Researcher at Wake Forest University
Publications - 16
Citations - 836
L. Doug Case is an academic researcher from Wake Forest University. The author has contributed to research in topics: Randomized controlled trial & Psychological intervention. The author has an hindex of 11, co-authored 16 publications receiving 699 citations. Previous affiliations of L. Doug Case include Bayer & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial
Stephen R. Rapp,L. Doug Case,Ann M. Peiffer,Michelle M. Naughton,Michael D. Chan,Volker W. Stieber,Dennis F. Moore,Steven Charles Falchuk,James Piephoff,William Jeffery Edenfield,Jeffrey K. Giguere,Monica Loghin,Edward G. Shaw +12 more
TL;DR: Treatment with donepezil did not significantly improve the overall composite score, but it did result in modest improvements in several cognitive functions, especially among patients with greater pretreatment impairments.
Journal ArticleDOI
Effectiveness of a Web-Based Colorectal Cancer Screening Patient Decision Aid: A Randomized Controlled Trial in a Mixed-Literacy Population
TL;DR: The web-based decision aid increased patients' ability to form a test preference and their intent to receive screening, regardless of literacy level, and similar results were found across literacy levels.
Journal Article
Tumor uptake and elimination of 2', 2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer : Correlation with in vivo tumor response
A. William Blackstock,Harry M. Lightfoot,L. Doug Case,Joel E. Tepper,Suresh K. Mukherji,Beverly S. Mitchell,Steve G. Swarts,Suzanne M. Hess +7 more
TL;DR: The hypothesis that increased expression of dCK cDNA in HT-29 xenografts results in an enhanced dFdCTP accumulation and prolonged elimination kinetics, and ultimately a potentiated in vivo tumor response to dDdCyd is supported.
Journal ArticleDOI
A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer.
TL;DR: It is suggested that clinically meaningful decreases in HRQOL, as measured by the FACT-P instrument, are evident within weeks after PIB, and a validated instrument designed to measure urinary symptoms (IPSS) demonstrates that moderate to severe urinary symptoms persist for at least 3-6 months following PIB.
Journal ArticleDOI
Staging by Positron Emission Tomography Predicts Survival in Patients With Non-small Cell Lung Cancer
Donnie P. Dunagan,Robert Chin,Trent W. Mc Cain,L. Doug Case,Beth A. Harkness,Timothy E. Oaks,Edward F. Haponik +6 more
TL;DR: PET scanning is a highly sensitive technologic advance in detecting and staging of thoracic malignancy and may more accurately predict the likelihood of long-term survival in patients with NSCLC than chest CT does.